Apolipoprotein E (ApoE) and Metabolism

NCT03109561 | Completed

• 1 other identifier: 17-0202-F1G
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Impaired metabolism and the gene apolipoprotein E (ApoE) are independent risk factors for cognitive impairment and dementia. In humans, there are three major versions of apoE (E): E2, E3, and E4. Some studies suggest that the different versions of apoE have varying effects on whole body and brain metabolism. The goal of this project is to better understand the relationship between apoE and metabolism. This will help investigators identify new targets for the prevention and treatment of cognitive decline and dementia.

Conditions

Cognitive Function; Healthy

Outcome Measures

Primary Outcomes (1)

• Indirect Calorimetry

  Measure resting state respiratory quotient in cognitively normal participants with various ApoE genotypes

  4 hours

Secondary Outcomes (1)

• Respiratory Quotient (RQ)

  4 hours

Other Outcomes (2)

• Urea Nitrogen Output

  4 hours

• Genotype

  4 hours

Interventions

Resting State Indirect Calorimetry OTHER

The investigator will measure the amount of oxygen participants breathe in and the amount of carbon dioxide they breathe out using a portable unit. Participants will be asked wearing a loose-fitting face mask that measures oxygen intake and carbon dioxide output.

ApoE GENETIC

The investigator will conduct a genetic test on DNA isolated from from the participants blood. Participants will be asked to provide about 2 tablespoons.

Metabolism DIAGNOSTIC_TEST

To more accurately measure the amount of carbohydrates, fats and proteins that the participants bodies metabolize, participants will be asked to provide two urine samples (one at the beginning, and one at the end, of the study). The total amount of urine to be collected is approximately 4 teaspoons.

Cognitive Challenge OTHER

Participants will be asked to follow simple instructions that are displayed on computer screen.

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Cognitively normal and are in good overall health.

You may qualify if:

• all races/ethnicities
• ages 18-65
• cognitively normal
• good health

You may not qualify if:

• pregnant or breastfeeding.
• have a bleeding disorder,
• have a history of stroke, seizures, Parkinson's disease, history of head injury with loss of consciousness, or other dementing disorder.
• have a history of alcoholism or drug abuse
• have a history of schizophrenia or currently suffer from bipolar disorder or major depression.
• have vision or hearing loss severe enough to interfere with cognitive testing

Sponsors & Collaborators

• Lance Johnson: lead

Study Sites (1)

University of Kentucky Medical Center

Lexington, Kentucky, 40536, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

2 tablespoons of blood for DNA Testing

MeSH Terms

Interventions

Apolipoproteins E; Metabolism

Intervention Hierarchy (Ancestors)

Apolipoproteins; Lipoproteins; Lipids; Apoproteins; Proteins; Amino Acids, Peptides, and Proteins

Study Officials

• Lance Johnson1, PhD

  University of Kentucky

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: April 6, 2017
• First Posted: April 12, 2017
• Study Start: April 24, 2018
• Primary Completion: January 30, 2020
• Study Completion: January 30, 2020
• Last Updated: July 23, 2020

Record last verified: 2020-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)